Plague vaccine

Last updated
Plague vaccine
Man being injected by doctor, during the outbreak of bubonic Wellcome V0029287.jpg
Plague vaccine being administered
Vaccine description
Target Yersinia pestis
Vaccine type Attenuated
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
ATC code
Identifiers
ChemSpider
  • none
UNII
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Plague vaccine is a vaccine used against Yersinia pestis to prevent the plague. [1] Inactivated bacterial vaccines have been used since 1890 but are less effective against the pneumonic plague, so live, attenuated vaccines and recombinant protein vaccines have been developed to prevent the disease. [2]

Plague immunization

The first plague vaccine was developed by bacteriologist Waldemar Haffkine in 1897. [3] [4] He tested the vaccine on himself to prove that the vaccine was safe. [4] [5] Later, Haffkine conducted a massive inoculation program in British India, and it is estimated that 26 million doses of Haffkine's anti-plague vaccine were sent out from Bombay between 1897 and 1925, reducing the plague mortality by 50%-85%. [3] [6]

A plague vaccine is used for an induction of active specific immunity in an organism susceptible to plague by means of administrating an antigenic material (a vaccine) via a variety of routes to people at risk of contracting any clinical form of plague. This method is known as plague immunization. There is strong evidence for the efficacy of administration of some plague vaccines in preventing or ameliorating the effects of a variety of clinical forms of infection by Yersinia pestis . Plague immunization also encompasses incurring a state of passive specific immunity to plague in a susceptible organism after administration of a plague serum or plague immunological in people with an immediate risk of developing the disease. [7]

A systematic review by the Cochrane Collaboration found no studies of sufficient quality to be included in the review, and were thus unable to make any statement on the efficacy of modern vaccines. [8]

Related Research Articles

<span class="mw-page-title-main">Plague (disease)</span> Disease caused by Yersinia pestis bacterium

Plague is an infectious disease caused by the bacterium Yersinia pestis. Symptoms include fever, weakness and headache. Usually this begins one to seven days after exposure. There are three forms of plague, each affecting a different part of the body and causing associated symptoms. Pneumonic plague infects the lungs, causing shortness of breath, coughing and chest pain; bubonic plague affects the lymph nodes, making them swell; and septicemic plague infects the blood and can cause tissues to turn black and die.

<span class="mw-page-title-main">Cholera</span> Bacterial infection of the small intestine

Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae. Symptoms may range from none, to mild, to severe. The classic symptom is large amounts of watery diarrhea lasting a few days. Vomiting and muscle cramps may also occur. Diarrhea can be so severe that it leads within hours to severe dehydration and electrolyte imbalance. This may result in sunken eyes, cold skin, decreased skin elasticity, and wrinkling of the hands and feet. Dehydration can cause the skin to turn bluish. Symptoms start two hours to five days after exposure.

<span class="mw-page-title-main">Vaccine</span> Pathogen-derived preparation that provides acquired immunity to an infectious disease

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

<i>Yersinia pestis</i> Species of bacteria, cause of plague

Yersinia pestis is a gram-negative, non-motile, coccobacillus bacterium without spores that is related to both Yersinia enterocolitica and Yersinia pseudotuberculosis, the pathogen from which Y. pestis evolved and responsible for the Far East scarlet-like fever. It is a facultative anaerobic organism that can infect humans via the Oriental rat flea. It causes the disease plague, which caused the Plague of Justinian and the Black Death, the deadliest pandemic in recorded history. Plague takes three main forms: pneumonic, septicemic, and bubonic. Yersinia pestis is a parasite of its host, the rat flea, which is also a parasite of rats, hence Y. pestis is a hyperparasite.

<span class="mw-page-title-main">Herd immunity</span> Concept in epidemiology

Herd immunity is a form of indirect protection that applies only to contagious diseases. It occurs when a sufficient percentage of a population has become immune to an infection, whether through previous infections or vaccination, thereby reducing the likelihood of infection for individuals who lack immunity.

In biology, immunity is the state of being insusceptible or resistant to a noxious agent or process, especially a pathogen or infectious disease. Immunity may occur naturally or be produced by prior exposure or immunization.

<span class="mw-page-title-main">Waldemar Haffkine</span> Russian-French microbiologist (1860–1930)

Waldemar Mordechai Wolff Haffkine, born Vladimir Aronovich (Markus-Volf) Khavkin was a Russian-French bacteriologist known for his pioneering work in vaccines.

<span class="mw-page-title-main">Third plague pandemic</span> Bubonic plague pandemic, beginning 1855

The third plague pandemic was a major bubonic plague pandemic that began in Yunnan, China, in 1855. This episode of bubonic plague spread to all inhabited continents, and ultimately led to more than 12 million deaths in India and China, and at least 10 million Indians were killed in British Raj India alone, making it one of the deadliest pandemics in history. According to the World Health Organization, the pandemic was considered active until 1960 when worldwide casualties dropped to 200 per year. Plague deaths have continued at a lower level for every year since.

<span class="mw-page-title-main">Meningococcal disease</span> Often life-threatening bacterial infection

Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.

Tuberculosis (TB) vaccines are vaccinations intended for the prevention of tuberculosis. Immunotherapy as a defence against TB was first proposed in 1890 by Robert Koch. Today, the only effective tuberculosis vaccine in common use is the Bacillus Calmette-Guérin (BCG) vaccine, first used on humans in 1921. It consists of attenuated (weakened) strains of the cattle tuberculosis bacillus. It is recommended for babies in countries where tuberculosis is common.

<span class="mw-page-title-main">Varicella vaccine</span> Vaccine to prevent chickenpox

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine are more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin. Another vaccine, known as zoster vaccine, is used to prevent diseases caused by the same virus – the varicella zoster virus.

<span class="mw-page-title-main">Vaccine efficacy</span> Reduction of disease among the vaccinated comparing to the unvaccinated

Vaccine efficacy or vaccine effectiveness is the percentage reduction of disease cases in a vaccinated group of people compared to an unvaccinated group. For example, a vaccine efficacy or effectiveness of 80% indicates an 80% decrease in the number of disease cases among a group of vaccinated people compared to a group in which nobody was vaccinated. When a study is carried out using the most favorable, ideal or perfectly controlled conditions, such as those in a clinical trial, the term vaccine efficacy is used. On the other hand, when a study is carried out to show how well a vaccine works when they are used in a bigger, typical population under less-than-perfectly controlled conditions, the term vaccine effectiveness is used.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

Immunization during pregnancy is the administration of a vaccine to a pregnant individual. This may be done either to protect the individual from disease or to induce an antibody response, such that the antibodies cross the placenta and provide passive immunity to the infant after birth. In many countries, including the US, Canada, UK, Australia and New Zealand, vaccination against influenza, COVID-19 and whooping cough is routinely offered during pregnancy.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

Pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae.

NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccine against the bacterium that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.

<span class="mw-page-title-main">Cholera vaccine</span> Vaccine to prevent cholera

A cholera vaccine is a vaccine that is effective at preventing cholera. The currently recommended cholera vaccines are administered orally to elicit a protective local mucosal immune response in the gut, which was poorly achieved with the injectable vaccines that were used until the 1970s. The first effective oral cholera vaccine was Dukoral, developed in Sweden in the 1980s. For the first six months after vaccination it provides about 85 percent protection, which decreases to approximately 60 percent during the first two years. When enough of the population is immunized, it may protect those who have not been immunized thereby increasing the total protective impact to more than 90 percent.

<span class="mw-page-title-main">Inactivated vaccine</span> Vaccine using a killed version of a disease pathogen

An inactivated vaccine is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.

References

  1. Plague+Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  2. Bubeck SS, Dube PH (September 2006). "Yersinia pestis CO92ΔyopH Is a Potent Live, Attenuated Plague Vaccine". Clin. Vaccine Immunol. 14 (9): 1235–8. doi:10.1128/CVI.00137-07. PMC   2043315 . PMID   17652523.
  3. 1 2 "Waldemar Haffkine: The vaccine pioneer the world forgot". BBC News. 2020-12-11. Retrieved 2021-01-20.
  4. 1 2 "WALDEMAR MORDECAI HAFFKINE". Haffkine Institute . Archived from the original on 2015-09-24. Retrieved 2021-01-20.
  5. Yang, Wei (July 2010). "[The pioneer of cholera vaccine and plague vaccine-Haffkine]". Zhonghua Yi Shi Za Zhi (Beijing, China: 1980). 40 (4): 243–246. ISSN   0255-7053. PMID   21122347.
  6. Hawgood, Barbara J. (February 2007). "Waldemar Mordecai Haffkine, CIE (1860-1930): prophylactic vaccination against cholera and bubonic plague in British India". Journal of Medical Biography. 15 (1): 9–19. doi:10.1258/j.jmb.2007.05-59. ISSN   0967-7720. PMID   17356724. S2CID   42075270.
  7. "WHO | Zoonotic Infections". www.who.int. Archived from the original on 22 March 2006. Retrieved 15 January 2022.
  8. Jefferson T, Demicheli V, Pratt M (2000). "Vaccines for preventing plague". Cochrane Database Syst Rev. 1998 (2): CD000976. doi:10.1002/14651858.CD000976. PMC   6532692 . PMID   10796565.